#Sovateltide #Pharmazz #StrokeTreatment #Neuropharmacology #CriticalCare #DrugDiscovery #NIPERMohali #ProfAnilGulati #BrainHealth
Mohali: In a landmark event highlighting the future of neurotherapeutics, Pharmazz, Inc., a biopharmaceutical company focused on critical care, showcased the discovery and clinical success of its novel stroke treatment drug, Sovateltide, at a two-day workshop organized by the Department of Pharmacology and Toxicology, NIPER, SAS Nagar (Mohali).
The workshop, titled “Drug Discovery and Development in New Millennium – 4 (D3NM-4),” brought together leading researchers, students, and pharmaceutical professionals under the theme “Interfacing with Emerging Neuroprotective Strategies & Neuropharmacological Techniques.”
Delivering the keynote address was Prof. Anil Gulati, Founder and CEO of Pharmazz, Inc., USA, and a distinguished figure in the field of neuropharmacology. Prof. Gulati spoke on “Discovery and development of Sovateltide to treat cerebral stroke patients,” tracing the 25-year-long research journey that led to the development of the groundbreaking drug.
A New Hope for Stroke Patients
Sovateltide is an endothelin-B receptor agonist, and is the first-in-class drug approved for the treatment of acute cerebral ischemic stroke in India. Prof. Gulati explained that the drug was developed after extensive preclinical and clinical studies that demonstrated statistically significant improvements in neurological recovery following ischemic stroke—a condition where blood flow to the brain is restricted due to a clot or blockage.
Sovateltide promotes neurogenesis, angiogenesis, and neural progenitor cell activation, offering a new mechanism for neurorepair. Unlike conventional stroke therapies that focus solely on restoring blood flow, Sovateltide helps in actual brain tissue regeneration and recovery.
“After more than two decades of research, what we have in Sovateltide is a promising therapy that not only saves lives but helps in meaningful neurological recovery,” Prof. Gulati stated. “It is rare for a molecule to evolve from bench to bedside in such a focused and transformative way.”
Regulatory Milestone and Real-World Impact
Sovateltide received regulatory approval in India in September 2023 and has since benefited over 70,000 patients through Pharmazz’s strategic commercial partner. The therapy is currently being used in multiple hospitals across the country, making a measurable impact in stroke management outcomes.
Preparations are also underway for a multinational Phase 3 trial, which would potentially pave the way for global approval and adoption. If successful, it could become a cornerstone drug for acute stroke treatment worldwide.
Pharmazz’s Expanding Pipeline
Pharmazz is rapidly emerging as a leader in the critical care biopharma space, with a growing pipeline of innovative therapies aimed at high-mortality and underserved conditions.
Alongside Sovateltide, the company currently has two drugs approved in India and two additional programs ready for Phase 3 trials in the United States. The focus areas include hypovolemic shock, cerebral ischemia, and other life-threatening conditions.
“Our commitment is to develop and deliver drugs where there is a true unmet medical need,” said Prof. Gulati. “We aim to transform patient outcomes not only in India but across the globe.”
Capacity Building in Neuropharmacology
The D3NM-4 workshop, hosted by NIPER Mohali, served as an important platform to discuss recent advancements in neuroprotective strategies and drug development techniques. More than 70 participants from leading institutes and colleges across Punjab, Himachal Pradesh, and Haryana took part in the event, engaging with interactive sessions, scientific talks, and expert-led discussions.
The program was designed to promote knowledge exchange between academic researchers and industry experts, while also exposing budding scientists to cutting-edge developments in pharmacological sciences.
The Department of Pharmacology and Toxicology at NIPER has consistently played a leadership role in advancing pharmacological research in India. The inclusion of a global breakthrough like Sovateltide in the academic conversation highlighted India’s growing contribution to global drug discovery efforts.
Looking Ahead
With India already witnessing the real-world impact of Sovateltide, the focus now shifts to global clinical validation and scaling access. As stroke remains a leading cause of death and long-term disability worldwide, the successful global rollout of a regenerative therapy like Sovateltide could mark a paradigm shift in neurological medicine.
The workshop at NIPER not only celebrated a milestone in drug development but also emphasized the importance of perseverance, innovation, and academic-industry collaboration in solving some of the world’s most pressing medical challenges.
🔖 Hashtags:
#Sovateltide #Pharmazz #StrokeTreatment #Neuropharmacology #CriticalCare #DrugDiscovery #NIPERMohali #ProfAnilGulati #BrainHealth #PharmaceuticalInnovation #IndianBiotech #Neuroprotection #MedicalBreakthrough #HealthcareInnovation
